Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Background CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated with considerable toxicity, providing the ration...

Full description

Bibliographic Details
Main Authors: Fabrice Barlesi, Steven Kao, Philippe A Cassier, Hua Fang, Frances Fan, Kathryn Allaire, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/2/e002015.full

Similar Items

Similar Items